Ibrutinib 140: Pioneering a Revolution in CLL Treatment
Chronic Lymphocytic Leukemia (CLL) has long posed a formidable challenge to the field of oncology. A slow-progressing, incurable blood cancer primarily affecting B-lymphocytes, CLL often leaves patients grappling with fatigue, swollen lymph nodes, and increased susceptibility to infections
